IL2 and neuroblastoma: It is worth noting that major advancements made towards the treatment of NB relate to the treatment of HRNB cases with an overall chance of survival of 20% at 2 years for patients treated with monoclonal antibody ch14.18 and anti-GD2 antibody plus granulocyte-macrophage colony-stimulating factor (GMCSF) and interleukin-2 [6,7].